US EditionNEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts – EastMud
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts
HONG KONG, Aug 5, 2025 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China's National Medical Products Administration (NMPA). This approval for production expansion will further boost capacity and increase product supply, enabling a more efficient response to the growing clinical demand in China and across Asia.NEFECON…
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts – EastMud
HONG KONG, Aug 5, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s National Medical Products Administration (NMPA). This approval for production expansion will further boost capacity and increase product supply, enabling a more efficient response to the growing clinical demand in China and a…
HONG KONG, August 5, 2025 – (Asia Pacific Business News via SeaPRwire.com) – Everest Medicines (HKEX: 1952.HK) today announced that it has received approval from the China National Medical Products Administration (NMPA) for its supplemental application for production expansion of Naifukang® (budesonide enteric-coated capsules), China's first and only fully approved causal treatment for IgA nephropathy. This further enhances the product's availab…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
